Evaluation of Injection Techniques in Celiac Plexus Neurolysis

Evaluation of Injection Techniques in Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis (EUS-CPN)

1. To evaluate the efficacy of EUS-CPN in subjects who experience a sympathetic response during injection when compared with subjects who do not experience sympathetic response during injection.

EUS-CPN when performed in subjects who experience a sympathetic response during injection will have better pain relief when compared to subjects who do not experience a sympathetic response during injection.

Study Overview

• Status: Completed
• Conditions: Pain; Pancreatic Cancer
• Intervention / Treatment: Other: Sympathetic response; Other: no sympathetic response

Detailed Description

1. All adult patients with radiologically consistent pancreatic carcinoma referred to Florida Hospital to undergo EUS for staging and diagnostic FNA of pancreatic mass lesions will be eligible for study entry.

   A history and physical examination will be performed to determine the character and quality of the pain and to evaluate for any contraindication for which EUS cannot be performed.

2. Written informed consent for study participation will be obtained at the same time as the consent for the procedure as this study is comparing standard of care treatment options in a regular treatment setting. Then, after giving written informed consents and prior to the index procedure, all patients will complete the following written assessments:

   1. Standardized 11-point continuous visual analog pain scale (12)
   2. Quality of life instruments: Functional Assessment of Cancer Therapy, Pancreatic Cancer (FACT-PA) (i.e. QLQ-30 and PAN-26) (13)
   3. Pain medication usage over prior 2 days (converted to equianalgesic doses of morphine)
3. EUS will be performed in standard fashion by one of three experienced endoscopists

4. Eligible patients will be included if pancreatic carcinoma is confirmed by FNA performed during EUS and if EUS or CT staging shows unresectability of the tumor. Cytology evaluation of FNA is routinely provided during procedure by pathologist into the endoscopy room at our institution.

   During EUS, included patients will receive CPN in the standard fashion. Whether a sympathetic response occurs or not during CPN, this will be documented. Sympathetic response will be defined as change in heart rate by >10 bpm and change in BP <10mmHg. The technique of EUS-CPN is as follows:

   • Using a curvilinear array echoendosocpe, the region of the celiac plexus is visualized from the lesser curvature of the stomach by following the aorta to the origin of the main celiac artery. It is traced, by using counter-clockwise rotation, to its bifurcation into splenic and hepatic arteries, with Doppler US control if needed.
   • CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin.
   • A 20-gauge fenestrated CPN needle is used, its tip is placed slightly anterior and cephalic to the origin of the celiac artery.
   • Aspiration is first performed to ensure that vascular puncture has not occurred.
   • Bupivacaine is injected first, followed by alcohol.
   • Patients will be observed for 2 to 4 hours, with careful monitoring of pulse, blood pressure and temperature.
5. Following EUS, patients will be discharged and called at home by research nurse at 24 hours for evidence of pancreatitis or other complications from the procedure, Clinical research nurse* will also contact the patient at 1, 2, 4 weeks after EUS and then monthly until death or 1 year. Clinical research nurse* will be blinded to the documentation about sympathetic response. Assessment of pain scale, QOL, medication use and side effects will be performed.
6. Following CPN, EUS operator will not be actively involved in patient care.
7. Medical decisions for each patient will be made by the patient's primary physician and oncologist.
8. Patient can be referred for rescue CPN if the patient's primary physician and oncologist feel that this is warranted.

• Study Type: Interventional
• Enrollment (Actual): 51
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Orlando, Florida, United States, 32803
      • Florida Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 89 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Abdominal pain typical for pancreatic cancer ( pain score ≥ 3/10)
2. Abdominal CT consistent with diagnosis of pancreatic cancer
3. Pancreatic cancer confirmed by EUS-FNA
4. Inoperable pancreatic cancer as determined during EUS or prior CT

Exclusion Criteria:

1. Age under 19 years
2. Unable to safely undergo EUS for any reason
3. Coagulopathy (Prothrombin time > 18 secs, platelet count < 80,000/ml)
4. Previous CPN or other neurolytic block that could affect pancreatic cancer-related pain or had implanted epidural or intrathecal analgesic therapy
5. Another cause for abdominal pain such as pseudocyst, ulcer or other intrabdominal disorder
6. Noncompliance such that the patient would not return for subsequent follow-up
7. Active alcohol or other drug use or significant psychiatric illness
8. Unable to consent
9. Non-English speaking

Study Plan

How is the study designed?

Design Details

• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: sympathetic response; This group will be composed of subjects who experience a heart rate and/or Blood Pressure change during injection.	Other: Sympathetic response; Sympathetic response will be defined as change in heart rate by >10 bpm and change in BP <10mmHg.
Other: no sympathetic response; This group will be made up of subjects that do not experience a vital sign change with injection for CPN.	Other: no sympathetic response; no Sympathetic response will be defined as change in heart rate by <10 bpm and change in BP <10mmHg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
abdominal pain	The primary endpoint of the study is abdominal pain. It will be assessed with a standardized 11-point continuous visual analog pain scale with "0" equaling no pain, "5" moderate pain and "10" worst pain ever. Before the procedure, patient will be instructed in the use of the pain scale by the research nurse. After the procedure, pain scores will be assessed by the clinical research nurse at the predetermined intervals. A complete response will be defined as an absence of abdominal pain requiring no pain medications. A partial response will be defined as a greater than 50% reduction in abdominal pain as assessed by the numerical 0-10 pain score. Failure will be defined as a reduction of ≤20% in pain score.	within the first year post CPN

Collaborators and Investigators

• Sponsor: AdventHealth

Study record dates

Study Major Dates

• Study Start: August 1, 2013
• Primary Completion (Actual): November 1, 2014
• Study Completion (Actual): November 1, 2014

Study Registration Dates

• First Submitted: August 30, 2013
• First Submitted That Met QC Criteria: February 19, 2014
• First Posted (Estimate): February 21, 2014

Study Record Updates

• Last Update Posted (Estimate): April 14, 2016
• Last Update Submitted That Met QC Criteria: April 12, 2016
• Last Verified: April 1, 2016

More Information

Terms related to this study

• Other Study ID Numbers: 456550

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO